Zentalis Pharmaceuticals, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Zentalis Pharmaceuticals, Inc. has an operating margin of -283.6%, meaning the company retains $-284 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Zentalis Pharmaceuticals, Inc. carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.32, Zentalis Pharmaceuticals, Inc. holds $7.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Zentalis Pharmaceuticals, Inc. generated -$170.9M in operating cash flow, capex of $221K consumed most of it, leaving -$171.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Zentalis Pharmaceuticals, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Zentalis Pharmaceuticals, Inc. generates $1.03 in operating cash flow (-$170.9M OCF vs -$165.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Zentalis Pharmaceuticals, Inc. (ZNTL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Zentalis Pharmaceuticals, Inc. generated $67.4M in revenue in fiscal year 2024.
Zentalis Pharmaceuticals, Inc.'s EBITDA was -$189.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.3% from the prior year.
Zentalis Pharmaceuticals, Inc. generated -$171.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 17.9% from the prior year.
Zentalis Pharmaceuticals, Inc. reported -$165.8M in net income in fiscal year 2024. This represents an increase of 43.2% from the prior year.
Zentalis Pharmaceuticals, Inc. earned $-2.33 per diluted share (EPS) in fiscal year 2024. This represents an increase of 47.9% from the prior year.
Zentalis Pharmaceuticals, Inc. held $33.9M in cash against $0 in long-term debt as of fiscal year 2024.
Zentalis Pharmaceuticals, Inc. had 71M shares outstanding in fiscal year 2024. This represents an increase of 0.7% from the prior year.
Zentalis Pharmaceuticals, Inc.'s operating margin was -283.6% in fiscal year 2024, reflecting core business profitability.
Zentalis Pharmaceuticals, Inc.'s net profit margin was -246.0% in fiscal year 2024, showing the share of revenue converted to profit.
Zentalis Pharmaceuticals, Inc. invested $167.8M in research and development in fiscal year 2024. This represents a decrease of 11.5% from the prior year.
Zentalis Pharmaceuticals, Inc. invested $221K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 62.1% from the prior year.
ZNTL Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0-100.0% | $26.9M | $0-100.0% | $40.6M | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $22.9M-16.9% | $27.6M+1.3% | $27.2M-17.4% | $33.0M-31.9% | $48.4M-2.4% | $49.6M-3.8% | $51.6M+10.2% | $46.8M |
| SG&A Expenses | $10.8M+27.7% | $8.4M-20.2% | $10.6M-73.6% | $40.0M+138.7% | $16.8M+6.5% | $15.7M-3.8% | $16.4M+2.6% | $16.0M |
| Operating Income | -$33.7M+6.4% | -$36.1M+21.0% | -$45.6M+8.5% | -$49.8M+23.5% | -$65.1M-163.1% | -$24.8M+63.5% | -$67.9M-8.3% | -$62.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0+100.0% | -$205K-177.1% | $266K+86.0% | $143K+205.9% | -$135K-535.5% | $31K |
| Net Income | -$26.7M+0.7% | -$26.9M+44.3% | -$48.3M-1.7% | -$47.5M+46.2% | -$88.3M-976.8% | $10.1M+116.5% | -$60.9M-9.7% | -$55.5M |
| EPS (Diluted) | $-0.370.0% | $-0.37+44.8% | $-0.670.0% | $-0.67+46.0% | $-1.24-985.7% | $0.14+118.4% | $-0.76+3.8% | $-0.79 |
ZNTL Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $327.3M-7.0% | $351.7M-8.4% | $384.0M-10.8% | $430.3M-12.5% | $491.7M-11.8% | $557.5M+1.0% | $551.7M-5.8% | $585.7M |
| Current Assets | $288.3M-7.5% | $311.6M-9.1% | $342.9M-11.2% | $386.1M-12.2% | $439.6M-12.7% | $503.8M+1.4% | $496.7M-6.0% | $528.3M |
| Cash & Equivalents | $39.1M+3.9% | $37.6M-10.3% | $41.9M+23.7% | $33.9M-8.3% | $37.0M-1.7% | $37.6M+34.2% | $28.0M-74.7% | $110.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0 | $0 | $0-100.0% | $5.0M | N/A | N/A | $0 | N/A |
| Goodwill | N/A | N/A | N/A | $0-100.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M |
| Total Liabilities | $74.4M-3.7% | $77.2M-12.9% | $88.6M-4.8% | $93.2M-14.6% | $109.1M+10.5% | $98.7M-13.6% | $114.3M+10.1% | $103.8M |
| Current Liabilities | $37.2M-4.8% | $39.0M-21.1% | $49.4M-6.2% | $52.7M-20.9% | $66.7M+21.7% | $54.8M-21.0% | $69.4M+17.7% | $58.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $252.9M-7.9% | $274.5M-7.1% | $295.4M-12.4% | $337.2M-11.9% | $382.6M-16.6% | $458.8M+4.9% | $437.3M-9.2% | $481.8M |
| Retained Earnings | -$1.2B-2.4% | -$1.1B-2.4% | -$1.1B-4.6% | -$1.1B-9.1% | -$966.8M-10.0% | -$878.5M+1.1% | -$888.6M-7.4% | -$827.6M |
ZNTL Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.0M+22.3% | -$34.7M-6.3% | -$32.6M+17.8% | -$39.7M-13.0% | -$35.1M+32.4% | -$52.0M-28.0% | -$40.6M-5.0% | -$38.7M |
| Capital Expenditures | $0 | $0 | $0 | $0-100.0% | $181K+352.5% | $40K-76.9% | $173K+90.1% | $91K |
| Free Cash Flow | -$27.0M+22.3% | -$34.7M-6.3% | -$32.6M+17.8% | -$39.7M-12.4% | -$35.3M+32.1% | -$52.0M-27.6% | -$40.8M-5.2% | -$38.8M |
| Investing Cash Flow | $28.3M-6.8% | $30.4M-24.9% | $40.5M+25.4% | $32.3M-6.4% | $34.5M-44.0% | $61.5M+246.3% | -$42.1M+64.2% | -$117.5M |
| Financing Cash Flow | $115K | $0-100.0% | $189K | $0-100.0% | $9K+28.6% | $7K | $0-100.0% | $309K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZNTL Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -185.5% | N/A | -61.1% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | -176.7% | N/A | 24.8% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | 2.2% | N/A | N/A |
| Return on Assets | -8.2%-0.5pp | -7.6%+4.9pp | -12.6%-1.5pp | -11.0%+6.9pp | -17.9%-19.8pp | 1.8%+12.8pp | -11.0%-1.6pp | -9.5% |
| Current Ratio | 7.76-0.2 | 7.99+1.0 | 6.94-0.4 | 7.32+0.7 | 6.59-2.6 | 9.19+2.0 | 7.16-1.8 | 8.97 |
| Debt-to-Equity | 0.29+0.0 | 0.28-0.0 | 0.30+0.0 | 0.280.0 | 0.29+0.1 | 0.22-0.0 | 0.26+0.0 | 0.22 |
| FCF Margin | N/A | N/A | N/A | -147.8% | N/A | -128.2% | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Zentalis Pharmaceuticals, Inc.'s annual revenue?
Zentalis Pharmaceuticals, Inc. (ZNTL) reported $67.4M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Zentalis Pharmaceuticals, Inc. profitable?
No, Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net income of -$165.8M in fiscal year 2024, with a net profit margin of -246.0%.
What is Zentalis Pharmaceuticals, Inc.'s earnings per share (EPS)?
Zentalis Pharmaceuticals, Inc. (ZNTL) reported diluted earnings per share of $-2.33 for fiscal year 2024. This represents a 47.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Zentalis Pharmaceuticals, Inc.'s EBITDA?
Zentalis Pharmaceuticals, Inc. (ZNTL) had EBITDA of -$189.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Zentalis Pharmaceuticals, Inc.'s operating margin?
Zentalis Pharmaceuticals, Inc. (ZNTL) had an operating margin of -283.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Zentalis Pharmaceuticals, Inc.'s net profit margin?
Zentalis Pharmaceuticals, Inc. (ZNTL) had a net profit margin of -246.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Zentalis Pharmaceuticals, Inc.'s free cash flow?
Zentalis Pharmaceuticals, Inc. (ZNTL) generated -$171.1M in free cash flow during fiscal year 2024. This represents a 17.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Zentalis Pharmaceuticals, Inc.'s operating cash flow?
Zentalis Pharmaceuticals, Inc. (ZNTL) generated -$170.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Zentalis Pharmaceuticals, Inc.'s total assets?
Zentalis Pharmaceuticals, Inc. (ZNTL) had $430.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Zentalis Pharmaceuticals, Inc.'s capital expenditures?
Zentalis Pharmaceuticals, Inc. (ZNTL) invested $221K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Zentalis Pharmaceuticals, Inc. spend on research and development?
Zentalis Pharmaceuticals, Inc. (ZNTL) invested $167.8M in research and development during fiscal year 2024.
How many shares does Zentalis Pharmaceuticals, Inc. have outstanding?
Zentalis Pharmaceuticals, Inc. (ZNTL) had 71M shares outstanding as of fiscal year 2024.
What is Zentalis Pharmaceuticals, Inc.'s current ratio?
Zentalis Pharmaceuticals, Inc. (ZNTL) had a current ratio of 7.32 as of fiscal year 2024, which is generally considered healthy.
What is Zentalis Pharmaceuticals, Inc.'s debt-to-equity ratio?
Zentalis Pharmaceuticals, Inc. (ZNTL) had a debt-to-equity ratio of 0.28 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zentalis Pharmaceuticals, Inc.'s return on assets (ROA)?
Zentalis Pharmaceuticals, Inc. (ZNTL) had a return on assets of -38.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Zentalis Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2024 data, Zentalis Pharmaceuticals, Inc. (ZNTL) had $33.9M in cash against an annual operating cash burn of $170.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Zentalis Pharmaceuticals, Inc.'s Piotroski F-Score?
Zentalis Pharmaceuticals, Inc. (ZNTL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Zentalis Pharmaceuticals, Inc.'s earnings high quality?
Zentalis Pharmaceuticals, Inc. (ZNTL) has an earnings quality ratio of 1.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals, Inc. (ZNTL) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.